BioNTech (NASDAQ:BNTX) Given "Buy" Rating at HC Wainwright

BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $107.00 target price on the stock. HC Wainwright's price objective indicates a potential upside of 23.84% from the stock's previous close.

A number of other equities research analysts have also commented on the company. The Goldman Sachs Group decreased their price objective on BioNTech from $113.00 to $100.00 and set a "neutral" rating for the company in a research report on Wednesday, February 28th. BMO Capital Markets lowered their price objective on shares of BioNTech from $127.00 to $123.00 and set an "outperform" rating on the stock in a research report on Thursday, March 21st. JPMorgan Chase & Co. dropped their price objective on shares of BioNTech from $99.00 to $90.00 and set an "underweight" rating on the stock in a research note on Friday, March 22nd. Canaccord Genuity Group reissued a "buy" rating and set a $171.00 target price on shares of BioNTech in a research note on Thursday, March 21st. Finally, UBS Group dropped their price target on shares of BioNTech from $110.00 to $101.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $120.40.

BioNTech Trading Up 0.1 %

Shares of NASDAQ:BNTX traded up $0.06 during mid-day trading on Wednesday, hitting $86.40. The stock had a trading volume of 1,264,662 shares, compared to its average volume of 671,486. The company's 50 day moving average is $91.67 and its 200-day moving average is $97.64. BioNTech has a 12-month low of $85.21 and a 12-month high of $125.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. The company has a market cap of $20.54 billion, a PE ratio of 20.91 and a beta of 0.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. On average, sell-side analysts predict that BioNTech will post -1.67 EPS for the current year.

Institutional Trading of BioNTech

Large investors have recently made changes to their positions in the stock. Eagle Bay Advisors LLC acquired a new stake in BioNTech in the 2nd quarter worth approximately $33,000. State of Wyoming acquired a new stake in shares of BioNTech in the second quarter worth $26,000. CWM LLC boosted its holdings in shares of BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company's stock worth $26,000 after buying an additional 217 shares during the period. GAMMA Investing LLC grew its stake in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company's stock valued at $25,000 after buying an additional 150 shares during the last quarter. Finally, Frazier Financial Advisors LLC bought a new position in BioNTech in the 4th quarter worth $30,000. Institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.